Reuters - An allergy treatment from Swiss biotech company Cytos (CYTN.S) met its main target in a mid-stage trial, the group said on Friday, boosting its battered shares. Patients taking CYT003-QbG10 for allergic rhinoconjunctivitis in the Phase IIb study had significantly lower allergy symptoms and reported a better quality of life than those taking a placebo, Cytos said in a statement.
